Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 10/20 | 0.62 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | LOX | P28300 | 4/20 | 0.45 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171414 | 0.91 | LOXL2 (0.53) | LOXL2PARP1SMYD3ADORA1KDR | |
| SCHEMBL18922125 | 0.85 | SMYD3 (0.58) | LOXL2PARP1SMYD3ADORA1KDR | |
| SCHEMBL246824 | 0.85 | PARP1 (0.51) | LOXL2PARP1SMYD3ADORA1KDR | |
| SCHEMBL30542691 | 0.85 | PARP1 (0.51) | LOXL2PARP1SMYD3ADORA1KDR | |
| SCHEMBL245411 | 0.83 | PARP1 (0.50) | LOXL2PARP1SMYD3ADORA1KDR | |
| SCHEMBL31256801 | 0.83 | PARP1 (0.50) | LOXL2PARP1SMYD3ADORA1KDR | |
| Hydrochloric Acid SCHEMBL244051 | 0.83 | PARP1 (0.50) | LOXL2PARP1SMYD3ADORA1KDR | |
| SCHEMBL2642931 | 0.83 | PARP1 (0.50) | LOXL2PARP1SMYD3ADORA1KDR | |
| SCHEMBL14354793 | 0.83 | PARP1 (0.50) | LOXL2PARP1SMYD3ADORA1KDR | |
| SCHEMBL1346581 | 0.83 | PARP1 (0.50) | LOXL2PARP1SMYD3ADORA1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765789-B2 | 2-pyridinecarboxamide derivatives | MSD K.K. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8344003-B2 | 2-pyridinecarboxamide derivatives | MSD K. K. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7629362-B2 | 2-pyridine carboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | LOXL2 2232/4885PARP1 3678/4885SMYD3 3443/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | LOXL2 2252/4885PARP1 3629/4885SMYD3 3414/4885 |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | LOXL2 2232/4885PARP1 3678/4885SMYD3 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.